MTOR and lymphoma: However, dual pan-class PI3K/mTOR inhibitors were developed to overcome this multiple pathway issue and seem to do so in preclinical evidence [42], showing in vitro and in vivo preclinical antitumor activity in lymphomas as monotherapy and combination therapy [43].